Now showing items 1659-1678 of 4188

    • Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(aEuro) 

      Robak, T; Matutes, E; Catovsky, D; Zinzani, PL; Buske, C; Comm, ESMOG (OXFORD UNIV PRESS, 2015-09)
    • Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation 

      Lo, ASY; Taylor, JR; Farzaneh, F; Kemeny, DM; Dibb, NJ; Maher, J (PERGAMON-ELSEVIER SCIENCE LTD, 2008-03)
      Aberrant growth factor production is a prevalent mechanism in tumourigenesis. If T-cells responded positively to a cancer-derived cytokine, this might result in selective enhancement of function within the tumour ...
    • Health economic impact of liquid biopsies in cancer management. 

      IJzerman, MJ; Berghuis, AMS; de Bono, JS; Terstappen, LWMM (2018-12)
      <h4>Introduction</h4>Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are ...
    • Health-related quality of life among cancer patients in their last year of life: results from the PROFILES registry. 

      Raijmakers, NJH; Zijlstra, M; van Roij, J; Husson, O; Oerlemans, S; van de Poll-Franse, LV (2018-10)
      PURPOSE:The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of cancer patients stratified by four periods of time before death. PATIENTS AND METHODS:Between 2008 and 2015, ...
    • Health-related quality of life around the time of diagnosis in patients with bladder cancer. 

      Yu, EY-W; Nekeman, D; Billingham, LJ; James, ND; Cheng, KK; Bryan, RT; Wesselius, A; Zeegers, MP (2019-12)
      <h4>Objectives</h4>To quantify the health-related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two-factor model for the HRQoL questionnaire ...
    • Health-related quality of life results from the phase III CheckMate 067 study. 

      Schadendorf, D; Larkin, J; Wolchok, J; Hodi, FS; Chiarion-Sileni, V; Gonzalez, R; Rutkowski, P; Grob, J-J; Cowey, CL; Lao, C; Wagstaff, J; Callahan, MK; Postow, MA; Smylie, M; Ferrucci, PF; Dummer, R; Hill, A; Taylor, F; Sabater, J; Walker, D; Kotapati, S; Abernethy, A; Long, GV (2017-09)
      <h4>Background</h4>Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, ...
    • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. 

      Brahmer, JR; Rodríguez-Abreu, D; Robinson, AG; Hui, R; Csőszi, T; Fülöp, A; Gottfried, M; Peled, N; Tafreshi, A; Cuffe, S; O'Brien, M; Rao, S; Hotta, K; Zhang, J; Lubiniecki, GM; Deitz, AC; Rangwala, R; Reck, M (2017-12)
      <h4>Background</h4>In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung ...
    • HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients 

      Li, Z; Zhou, L; Prodromou, C; Savic, V; Pearl, LH (Elsevier BV, 2017-06)
    • Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. 

      Qian, F; Wang, S; Mitchell, J; McGuffog, L; Barrowdale, D; Leslie, G; Oosterwijk, JC; Chung, WK; Evans, DG; Engel, C; Kast, K; Aalfs, CM; Adank, MA; Adlard, J; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Arun, BK; Ausems, MGEM; Azzollini, J; Barouk-Simonet, E; Barwell, J; Belotti, M; Benitez, J; Berger, A; Borg, A; Bradbury, AR; Brunet, J; Buys, SS; Caldes, T; Caligo, MA; Campbell, I; Caputo, SM; Chiquette, J; Claes, KBM; Margriet Collée, J; Couch, FJ; Coupier, I; Daly, MB; Davidson, R; Diez, O; Domchek, SM; Donaldson, A; Dorfling, CM; Eeles, R; Feliubadaló, L; Foretova, L; Fowler, J; Friedman, E; Frost, D; Ganz, PA; Garber, J; Garcia-Barberan, V; Glendon, G; Godwin, AK; Gómez Garcia, EB; Gronwald, J; Hahnen, E; Hamann, U; Henderson, A; Hendricks, CB; Hopper, JL; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, Á; Jakubowska, A; Kaczmarek, K; Kang, E; Karlan, BY; Kets, CM; Kim, S-W; Kim, Z; Kwong, A; Laitman, Y; Lasset, C; Hyuk Lee, M; Won Lee, J; Lee, J; Lester, J; Lesueur, F; Loud, JT; Lubinski, J; Mebirouk, N; Meijers-Heijboer, HEJ; Meindl, A; Miller, A; Montagna, M; Mooij, TM; Morrison, PJ; Mouret-Fourme, E; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Nielsen, FC; Nussbaum, RL; Offit, K; Olah, E; Ong, K-R; Ottini, L; Park, SK; Peterlongo, P; Pfeiler, G; Phelan, CM; Poppe, B; Pradhan, N; Radice, P; Ramus, SJ; Rantala, J; Robson, M; Rodriguez, GC; Schmutzler, RK; Hutten Selkirk, CG; Shah, PD; Simard, J; Singer, CF; Sokolowska, J; Stoppa-Lyonnet, D; Sutter, C; Yen Tan, Y; Teixeira, RM; Teo, SH; Terry, MB; Thomassen, M; Tischkowitz, M; Toland, AE; Tucker, KM; Tung, N; van Asperen, CJ; van Engelen, K; van Rensburg, EJ; Wang-Gohrke, S; Wappenschmidt, B; Weitzel, JN; Yannoukakos, D; GEMO Study Collaborators; HEBON; EMBRACE; Greene, MH; Rookus, MA; Easton, DF; Chenevix-Trench, G; Antoniou, AC; Goldgar, DE; Olopade, OI; Rebbeck, TR; Huo, D (2019-04)
      <h4>Background</h4>BRCA1/2 mutations confer high lifetime risk of breast cancer, although other factors may modify this risk. Whether height or body mass index (BMI) modifies breast cancer risk in BRCA1/2 mutation carriers ...
    • Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. 

      Zhang, B; Shu, X-O; Delahanty, RJ; Zeng, C; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Wen, W; Long, J; Li, C; Dunning, AM; Chang-Claude, J; Shah, M; Perkins, BJ; Czene, K; Darabi, H; Eriksson, M; Bojesen, SE; Nordestgaard, BG; Nielsen, SF; Flyger, H; Lambrechts, D; Neven, P; Wildiers, H; Floris, G; Schmidt, MK; Rookus, MA; van den Hurk, K; de Kort, WLAM; Couch, FJ; Olson, JE; Hallberg, E; Vachon, C; Rudolph, A; Seibold, P; Flesch-Janys, D; Peto, J; Dos-Santos-Silva, I; Fletcher, O; Johnson, N; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Li, J; Humphreys, K; Brand, J; Guénel, P; Truong, T; Cordina-Duverger, E; Menegaux, F; Burwinkel, B; Marme, F; Yang, R; Surowy, H; Benitez, J; Zamora, MP; Perez, JIA; Cox, A; Cross, SS; Reed, MWR; Andrulis, IL; Knight, JA; Glendon, G; Tchatchou, S; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Chenevix-Trench, G; kConFab Investigators, Australian Ovarian Study Group; Haiman, CA; Henderson, BE; Schumacher, F; Marchand, LL; Lindblom, A; Margolin, S; Hooning, MJ; Martens, JWM; Tilanus-Linthorst, MMA; Collée, JM; Hopper, JL; Southey, MC; Tsimiklis, H; Apicella, C; Slager, S; Toland, AE; Ambrosone, CB; Yannoukakos, D; Giles, GG; Milne, RL; McLean, C; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Brenner, H; Dieffenbach, AK; Arndt, V; Stegmaier, C; Swerdlow, AJ; Ashworth, A; Orr, N; Jones, M; Figueroa, J; Garcia-Closas, M; Brinton, L; Lissowska, J; Dumont, M; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Brauch, H; Brüning, T; Ko, Y-D; Peterlongo, P; Manoukian, S; Bonanni, B; Radice, P; Bogdanova, N; Antonenkova, N; Dörk, T; Mannermaa, A; Kataja, V; Kosma, V-M; Hartikainen, JM; Devilee, P; Seynaeve, C; Van Asperen, CJ; Jakubowska, A; Lubiński, J; Jaworska-Bieniek, K; Durda, K; Hamann, U; Torres, D; Schmutzler, RK; Neuhausen, SL; Anton-Culver, H; Kristensen, VN; Grenaker Alnæs, GI; DRIVE Project; Pierce, BL; Kraft, P; Peters, U; Lindstrom, S; Seminara, D; Burgess, S; Ahsan, H; Whittemore, AS; John, EM; Gammon, MD; Malone, KE; Tessier, DC; Vincent, D; Bacot, F; Luccarini, C; Baynes, C; Ahmed, S; Maranian, M; Healey, CS; González-Neira, A; Pita, G; Alonso, MR; Álvarez, N; Herrero, D; Pharoah, PDP; Simard, J; Hall, P; Hunter, DJ; Easton, DF; Zheng, W (2015-11)
      <h4>Background</h4>Epidemiological studies have linked adult height with breast cancer risk in women. However, the magnitude of the association, particularly by subtypes of breast cancer, has not been established. Furthermore, ...
    • Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. 

      Lophatananon, A; Stewart-Brown, S; Kote-Jarai, Z; Olama, AAA; Garcia, SB; Neal, DE; Hamdy, FC; Donovan, JL; Giles, GG; Fitzgerald, LM; Southey, MC; Pharoah, P; Pashayan, N; Gronberg, H; Wiklund, F; Aly, M; Stanford, JL; Brenner, H; Dieffenbach, AK; Arndt, V; Park, JY; Lin, H-Y; Sellers, T; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Spurdle, A; Clements, JA; APCB BioResource; PRACTICAL consortium; Easton, D; Eeles, RA; Muir, K (2017-08)
      <h4>Background</h4>Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.<h4>Methods</h4>We ...
    • Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. 

      Vogelzang, NJ; Coleman, RE; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Widmark, A; Thuresson, M; Xu, L; Germino, J; Sartor, O (2017-02)
      <h4>Background</h4>Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; ...
    • Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods 

      Schild, LJ; Phillips, DH; Osborne, MR; Hewer, A; Beland, FA; Churchwell, MI; Brown, K; Gaskell, M; Wright, E; Poirier, MC (OXFORD UNIV PRESS, 2005-03)
      Liver homogenates from rats fed tamoxifen (TAM) in the diet were shared among four different laboratories. TAM-DNA adducts were assayed by high pressure liquid chromatography-electrospray tandem mass spectrometry ...
    • HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 

      Bartlett, JMS; Ahmed, I; Regan, MM; Sestak, I; Mallon, EA; Dell'Orto, P; Thurlimann, B; Seynaeve, C; Putter, H; Van de Velde, CJH; Brookes, CL; Forbes, JF; Viale, G; Cuzick, J; Dowsett, M; Rea, DW; Inhibitor, TA (2017-07)
    • HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. 

      Bartlett, JMS; Ahmed, I; Regan, MM; Sestak, I; Mallon, EA; Dell'Orto, P; Thürlimann, B; Seynaeve, C; Putter, H; Van de Velde, CJH; Brookes, CL; Forbes, JF; Viale, G; Cuzick, J; Dowsett, M; Rea, DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG) (2017-07)
      <h4>Background</h4>A meta-analysis of the effects of HER2 status, specifically within the first 2-3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor (AI) ...
    • HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. 

      Martins, CD; Da Pieve, C; Burley, TA; Smith, R; Ciobota, DM; Allott, L; Harrington, KJ; Oyen, WJG; Smith, G; Kramer-Marek, G (2018-04)
      Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ...